iBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference Call
Review of promising Myostatin and Activin E antibody data
iBio to announce 3rd target in Astral Bio Collaboration
Conference call Tuesday, June 24 at 8:30 a.m. ET
SAN DIEGO, June 23, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq: IBIO), an AI-driven innovator of precision antibody therapies, today announced the Company will host a conference call on Tuesday, June 24, at 8:30 a.m. ET to review its latest advances in obesity and cardiometabolic disease treatments and announce a third target in the AstralBio Collaboration in addition to Myostatin and Activin E.Martin Brenner, DVM, Ph.D., iBio's CEO and Chief Scientific Officer, will outline how iBio is pioneering the next generation of antibody medicines—targeted, longer-lasting, and potentially better tolerated therapies with more sustainable efficacy. Dr. Brenner will present a strategic overview of the obesity strategy, including details on their long acting Myostatin, IBIO-600, new preclinical data on Activin E and, more safe and effective treatment options.The webcast of the live call may be accessed on the Investors section of the iBio website at ir.ibioinc.com/news-events/ir-calendar. A replay of the webcast will be available on the iBio website for approximately 60 days following the presentation.To join the live call, participants need to access this link for dial-in numbers and a unique participation code.
About iBio, Inc.
iBio (Nasdaq: IBIO) is a cutting-edge biotech company leveraging AI and advanced computational biology to develop next-generation biopharmaceuticals for cardiometabolic diseases, obesity, cancer and other hard-to-treat diseases. By combining proprietary 3D modeling with innovative drug discovery platforms, iBio is creating a pipeline of breakthrough antibody treatments to address significant unmet medical needs. Our mission is to transform drug discovery, accelerate development timelines, and unlock new possibilities in precision medicine. For more information, visit www.ibioinc.com or follow us on LinkedIn.
Forward-Looking Statements
Any statements contained in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute 'forward-looking statements.' These statements include statements regarding pioneering the next generation of antibody medicines, which are potentially better tolerated therapies with more sustainable efficacy, and Activin E and amylin agonist, which are promising pathways for more safe and effective treatment options. The words 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including iBio's ability to obtain regulatory approvals for commercialization of its product candidates, or to comply with ongoing regulatory requirements; regulatory limitations relating to iBio's ability to promote or commercialize its product candidates for specific indications; acceptance of iBio's product candidates in the marketplace and the successful development, marketing or sale of products; and whether iBio will incur unforeseen expenses or liabilities or other market factors; and the other factors discussed in iBio's filings with the SEC including its Annual Report on Form 10-K for the year ended June 30, 2024 and its subsequent filings with the SEC on Forms 10-Q and 8-K. The information in this release is provided only as of the date of this release, and iBio undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.
Corporate Contact: iBio, Inc. Investor Relations ir@ibioinc.com
Media Contacts: Ignacio Guerrero-Ros, Ph.D., or David Schull Russo Partners, LLC Ignacio.guerrero-ros@russopartnersllc.com David.schull@russopartnersllc.com (858) 717-2310 or (646) 942-5604
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Shares cheered in Asia as Trump announces Iran-Israel ceasefire
(Corrects day in paragraph 1.) By Wayne Cole SYDNEY (Reuters) -Wall Street futures rose and the dollar eased in Asia on Tuesday after U.S. President Donald Trump said Iran and Israel had agreed to a ceasefire, sending oil prices into a deep dive as concerns over supply disruptions ebbed. Writing on his Truth Social site, Trump implied a ceasefire would go into effect in 12 hours and then the war would be considered "ended". Oil prices fell another 4%, having already slid 9% on Monday when Iran made a token retaliation against a U.S. base which came to nothing and signalled it was done for now. However, both Israel and Iran continued their missile strikes, making investors cautious about piling into risk assets just yet. "This lifts some of the geopolitical uncertainty surrounding the markets, although, for the most part, equity investors have been kind of shrugging the uncertainty off," said Jack Ablin, chief investment officer at Cresset Wealth Advisors in Palm Beach, Florida. "It certainly sounds like a significant milestone, and I hope it's true." With the immediate threat to the vital Strait of Hormuz shipping lane seemingly over, U.S. crude futures fell another 4% to $65.75 per barrel. S&P 500 futures gained 0.3% in early trade, while Nasdaq futures added 0.5%. Nikkei futures traded up at 38,905, well above the cash close of 38,354. Futures for 10-year Treasuries fell 6 ticks as the need for safe havens lessened, while interest rate futures slipped as investors rowed back a little on expectations for rate cuts. The market had rallied on Monday after Federal Reserve Vice Chair for Supervision Michelle Bowman said the time to cut interest rates was getting nearer as risks to the job market may be on the rise. Fed Chair Jerome Powell will have his own chance to comment when appearing before Congress later on Tuesday and, so far, has been more cautious about a near-term easing. Markets still only imply around a 22% chance the Fed will cut at its next meeting on July 30. News of the ceasefire saw the dollar extend an overnight retreat and slip 0.1% to 145.92 yen, while the euro edged up 0.1% to $1.1589. The yen and euro benefited from the slide in oil prices as both the EU and Japan rely heavily on imports of oil and liquefied natural gas, while the United States is a net exporter. The risk-on mood saw gold prices ease 0.4% to $3,353 an ounce. Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
WISeSat.Space and SEALSQ Launch New Satellite with SpaceX, Enabling the First-Ever DePIN from Space, and Advancing Quantum-Safe Space Communications
Geneva, Switzerland, June 23, 2025 (GLOBE NEWSWIRE) -- Courtesy of SpaceXSEALSQ Corp (NASDAQ: LAES) ("SEALSQ" or "Company"), a company that focuses on developing and selling Semiconductors, PKI, and Post-Quantum technology hardware and software products, today announced that SA ('WISeSat'), a subsidiary of its parent company, WISeKey International Holding Ltd (SIX: WIHN, NASDAQ: WKEY), has successfully launched its latest generation satellite WISeSat 3 aboard SpaceX's Falcon 9 Transporter-14 mission, June 23 at 23:18 CEST from Vanderberg, California. This mission represents a breakthrough in space-based cybersecurity and decentralized infrastructure, marking the first satellite to embed SEALSQ's Quantum RootKey. The new satellite includes cutting-edge technology enabling SEALCOIN token exchanges directly from space, in collaboration with Hedera. Of note, SEALCOIN AG, also a subsidiary of WISeKey, focuses on decentralized physical internet with DePIN technology and house the development of the SEALCOIN platform. This innovation establishes the world's first Decentralized Physical Infrastructure Network (DePIN) launched from orbit, transforming the role of satellites in decentralized finance and secure digital identity. Simultaneously, the mission is a pivotal step forward in securing space communications through the implementation of post-quantum cryptography (PQC). PQC is critical for protecting satellite communications against future threats posed by quantum computers, which are expected to render current encryption methods like RSA obsolete. Ensuring data integrity and confidentiality is essential in the space environment, and PQC delivers quantum-resistant algorithms that can be integrated into existing systems, allowing for a seamless transition and protection from both current and emerging risks. This satellite architecture supports the integration of PQC within a hybrid framework that enables secure communication between orbital and ground-based infrastructure. By embedding PQC algorithms directly into satellite hardware, the cryptographic processing is isolated from critical systems, thus enhancing security and minimizing vulnerabilities. This approach also allows for secure key generation, distribution, and management, essential functions for trusted data exchange between satellites and Earth stations. The cryptographic algorithms being tested onboard follow the latest standards under development by the U.S. National Institute of Standards and Technology (NIST), ensuring that the technology is aligned with global efforts to future-proof digital infrastructure. With this mission, WISeSat and SEALSQ are demonstrating how PQC can not only be deployed in terrestrial networks, but also extended into orbit, safeguarding critical communications for years to come. Carlos Moreira, Founder and CEO of SEALSQ, commented: 'This launch is not only a milestone for decentralized infrastructure in space, but also a strategic move toward making space communications quantum-resilient. By embedding PQC and enabling blockchain-based tokenization from orbit, we are reshaping the way cybersecurity, finance, and space technology converge.' Representing WISeSat at the launch was David Fergusson, Board Director of WISeKey, and Executive Managing Director, M&A at Generational Equity. Joining Mr. Fergusson, as a guest of WISeKey was Jon Templeman, CEO of Savior Products and a pioneer in battery technology. Mr. Templeman's latest innovation is an industry-disruptive 'shock and vibration management system' for application to all vehicles, from automobiles to rockets, increasing life-span and reducing material costs. Mr. Fergusson commented, 'WISeSat's groundbreaking innovation, pioneering the advancement of post-quantum cryptography, continues to set precedent for the future of trusted communication and data transmission. And it's an honor to be joined at this historic launch by Jon Templeman, a pioneer in his own right, whose advancements in battery technology will be transformative for companies like WISeSat.' The latest satellite launch forms part of a growing WISeSat constellation that delivers sovereign, secure, and scalable satellite services for IoT, digital identity, and trusted data transmission. The launch strengthens Europe's capabilities in space and cybersecurity, promoting technological independence and leadership in the age of quantum computing. About SEALSQ:SEALSQ is a leading innovator in Post-Quantum Technology hardware and software solutions. Our technology seamlessly integrates Semiconductors, PKI (Public Key Infrastructure), and Provisioning Services, with a strategic emphasis on developing state-of-the-art Quantum Resistant Cryptography and Semiconductors designed to address the urgent security challenges posed by quantum computing. As quantum computers advance, traditional cryptographic methods like RSA and Elliptic Curve Cryptography (ECC) are increasingly vulnerable. SEALSQ is pioneering the development of Post-Quantum Semiconductors that provide robust, future-proof protection for sensitive data across a wide range of applications, including Multi-Factor Authentication tokens, Smart Energy, Medical and Healthcare Systems, Defense, IT Network Infrastructure, Automotive, and Industrial Automation and Control Systems. By embedding Post-Quantum Cryptography into our semiconductor solutions, SEALSQ ensures that organizations stay protected against quantum threats. Our products are engineered to safeguard critical systems, enhancing resilience and security across diverse industries. For more information on our Post-Quantum Semiconductors and security solutions, please visit Forward-Looking StatementsThis communication expressly or implicitly contains certain forward-looking statements concerning SEALSQ Corp and its businesses. Forward-looking statements include statements regarding our business strategy, financial performance, results of operations, market data, events or developments that we expect or anticipate will occur in the future, as well as any other statements which are not historical facts. Although we believe that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates which are inherently subject to significant uncertainties and contingencies, many of which are beyond our control. Actual results may differ materially from those expressed or implied by such forward-looking statements. Important factors that, in our view, could cause actual results to differ materially from those discussed in the forward-looking statements include SEALSQ's ability to continue beneficial transactions with material parties, including a limited number of significant customers; market demand and semiconductor industry conditions; and the risks discussed in SEALSQ's filings with the SEC. Risks and uncertainties are further described in reports filed by SEALSQ with the SEC. SEALSQ Corp is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. SEALSQ MoreiraChairman & CEOTel: +41 22 594 3000info@ SEALSQ Investor Relations (US)The Equity Group CatiTel: +1 212 836-9611 lcati@
Yahoo
an hour ago
- Yahoo
Serina Therapeutics to Present at FORCE Family Office Investor Webinar on June 26, 2025
How Parkinson's affects million – and why current treatments are not enough Continuous dopaminergic stimulation (CDS): a next-gen approach to Parkinson's care Serina's drug candidate SER-252 is designed to deliver continuous symptom relief Join Serina CEO Steve Ledger for this live event hosted by FORCE Family Office HUNTSVILLE, AL, June 23, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ('Serina') (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, is pleased to announce that Chief Executive Officer Steve Ledger will present at an upcoming FORCE Family Office investor webinar titled "New Drug Optimization Platform to Transform Parkinson's Care.' The Event is scheduled to take place on Thursday, June 26, 2025, at 12:00 p.m. ET / 9:00 a.m. PT. In this presentation, Mr. Ledger will discuss how advanced Parkinson's disease impacts millions of people worldwide by affecting their ability to move and maintain quality of life. He will highlight the limitations of current medications, which often wear off quickly or cause unwanted side effects like tremors or stiffness. SER-252 is Serina's propriety polymer conjugate of apomorphine, a clinically proven dopamine agonist, which is designed to deliver continuous dopaminergic stimulation (CDS), which aims to provide smoother, longer-lasting symptom control and greater convenience. The discussion will also explore the unique advantages of Serina's POZ Platform™, a next-generation drug optimization system with the potential to improve the safety, duration, and tolerability of Parkinson's treatments and other therapeutics. The webinar will be hosted by FORCE Family Office CEO, Steve Saltzstein, and include a Q&A session. Attendees may submit questions via the online chat feature during the event. To register for the complimentary event, please visit: Serina Therapeutics Serina is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. Serina's POZ Platform™ provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics, and antibody-based drug conjugates (ADCs). Serina is headquartered in Huntsville, Alabama on the campus of the HudsonAlpha Institute of Biotechnology. For more information, please visit About FORCE Family Office FORCE is the largest network of Family Offices, Foundations, Endowments, and individual accredited investors in the United States. They introduce members of their network to leaders of public companies and privately held businesses at the capital acquisition stage. In addition, they facilitate co-investment opportunities, information sharing, philanthropy, and networking among their elite, peer-to-peer community. More information can be found at Cautionary Statement Regarding Forward-Looking Statement This release contains forward-looking statements within the meaning of federal securities laws. These statements are based on management's current expectations, plans, beliefs, or forecasts for the future, and are subject to uncertainty and changes in circumstances. Any express or implied statements in this press release that are not statements of historical fact, including statements about the potential of Serina's POZ polymer technology, are forward-looking statements that involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when any applications may be filed for any drug or vaccine candidates in any jurisdictions; whether and when regulatory authorities may approve any potential applications that may be filed for any drug or vaccine candidates in any jurisdictions, which will depend on a myriad of factors, including making a determination as to whether the product's benefits outweigh its known risks and determination of the product's efficacy and, if approved, whether any such drug or vaccine candidates will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of any drug or vaccine candidates; and competitive developments. These risks as well as other risks are more fully discussed in Serina's Annual Report on Form 10-K, and Serina's other periodic reports and documents filed from time to time with the SEC. The information contained in this release is as of the date hereof, and Serina assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments. The information contained in this release is as of the date hereof, and Serina assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments. For inquiries, please contact:Stefan Rileysriley@ 327-9630Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
